Treatment Overview
Minimally Invasive MicroSclerostomy in Korea is an advanced MIGS (Minimally Invasive Glaucoma Surgery) technique that creates a tiny, controlled outflow channel through the sclera to lower intraocular pressure (IOP). Unlike traditional filtering surgeries such as trabeculectomy, MicroSclerostomy uses micro-precision instrumentation to create a micro-tunnel that allows aqueous humor to exit the anterior chamber with far less trauma, faster recovery, and reduced risk of complications.
Leading Korean ophthalmology centers enhance the procedure with OCT-guided scleral thickness mapping, AI-assisted outflow modeling, micro-incision access, and flow-regulated micro-tunnel engineering. The result is a safe, predictable, and highly effective outflow pathway with minimal tissue disruption—ideal for patients requiring more pressure reduction than standard MIGS but less invasiveness than traditional filtration surgery.
Purpose & Benefits
Purpose
- Create a controlled micro-scleral outflow channel to reduce IOP.
- Provide an alternative to trabeculectomy with fewer risks and faster healing.
- Treat mild, moderate, and select cases of advanced glaucoma.
- Lower medication burden in patients with medication intolerance or resistance.
Benefits
- Minimally Invasive: Smaller incision, less tissue disruption, and shorter healing time.
- Controlled Outflow: Reduces risk of hypotony seen in traditional filtering surgeries.
- Predictable Pressure Reduction: Suitable for patients needing moderate to significant IOP lowering.
- No Large Bleb Formation: Micro-sclerostomy results in a low-profile or micro-filtration area.
- Fewer Complications: Much lower risk than full-thickness filtering surgeries.
- Fast Recovery: Mild discomfort, minimal inflammation, rapid visual recovery.
- May Be Combined With Other MIGS: Enhances overall pressure-lowering effect.
Ideal Candidates
Minimally Invasive MicroSclerostomy in Korea is ideal for:
- Patients with moderate to advanced open-angle glaucoma needing IOP reduction beyond standard MIGS.
- Individuals intolerant or unresponsive to glaucoma medications.
- Those seeking a safer, gentler alternative to trabeculectomy.
- Patients with high risk for scarring or filtration complications.
- Individuals with accessible scleral anatomy and healthy conjunctival tissue.
- Patients undergoing combined cataract + MIGS for greater pressure reduction.
Possible Risks & Complications
MicroSclerostomy is far safer than conventional filtration surgeries, but mild side effects may occur:
- Transient inflammation
- Mild subconjunctival fluid collection
- Temporary blurred vision
- Short-term IOP fluctuations
- Rare micro-leakage or tunnel narrowing
Korean surgeons minimize risks using:
- AI-based scleral thickness assessment
- Micro-precision tunnel creation tools
- OCT-guided depth control
- Anti-fibrotic modulation when needed
Surgical Techniques
1. AI-Driven Outflow Planning
Analyzes scleral structure and predicts optimal micro-tunnel characteristics.
2. Micro-Incision Access
A tiny corneal or limbal incision allows entry to create the outflow channel.
3. Microsclerostomy Creation
A calibrated micro-blade or laser system forms a narrow, controlled tunnel through the sclera.
4. Controlled Filtration Flow
The micro-tunnel allows aqueous humor to flow out in a regulated manner, avoiding hypotony.
5. Anti-Fibrotic Optimization (If Needed)
Low-dose agents may be used to prevent tunnel closure.
6. Imaging-Based Verification
OCT and ultrasound biomicroscopy ensure correct depth, tunnel patency, and optimal positioning.
Treatment Process in Korea
Step-by-Step Workflow
Step 1 – Comprehensive Evaluation
Includes IOP measurement, OCT, visual fields, scleral mapping, and conjunctival assessment.
Step 2 – Surgical Planning
AI models determine tunnel size, angle, and filtration zone.
Step 3 – Micro-Incision Entry
A small incision gives access for tunnel creation.
Step 4 – Minimally Invasive MicroSclerostomy
A precise micro-scleral channel is created for controlled aqueous outflow.
Step 5 – Postoperative Monitoring
Surgeons track tunnel patency, IOP stability, and conjunctival healing.
Treatment Duration: 10–15 minutes
Setting: Outpatient, same-day discharge
Recovery & After-Care
After-Care Guidelines
- Use anti-inflammatory and antibiotic drops for 2–4 weeks.
- Avoid rubbing the eye or engaging in strenuous activities for 1 week.
- Wear UV-protective sunglasses outdoors.
- Attend all postoperative check-ups (Day 1, Week 1, Month 1, Month 3).
- Continue medications unless instructed to taper.
Recovery Timeline
Days 1–3: Mild irritation or subconjunctival fluid; early pressure reduction.
Week 1: Clearer vision and stable filtration flow.
Weeks 2–4: Strong IOP reduction; possible medication taper.
1–3 Months: Long-term tunnel stability and optimized outflow.
Results & Longevity
Expected Results
- Significant IOP reduction in moderate to advanced glaucoma.
- Less inflammation and scarring than traditional filtration surgeries.
- Safer and gentler than trabeculectomy with similar pressure-lowering potential.
- Medication burden often reduced substantially.
Longevity
- MicroSclerostomy results often last years, especially with proper follow-up.
- Korean clinics use advanced anti-fibrotic strategies to prevent tunnel closure.
- Additional MIGS can be added later if needed.
Why Korea Is a Top Destination
- Pioneers in Micro-Filtration MIGS: Korean surgeons excel in safe scleral micro-tunneling techniques.
- High-Resolution Imaging: OCT and UBM ensure precise tunnel creation.
- AI-Enhanced Surgical Planning: Personalized flow modeling and scleral mapping.
- Minimally Invasive Protocols: Tiny incisions, rapid recovery, minimal pain.
- Outstanding Long-Term Pressure Control: Exceptional clinical outcomes with lower complication rates.
Unique Korean Innovations
- AI-assisted scleral micro-tunnel design
- OCT-guided depth control for perfect tunnel placement
- Anti-fibrotic micro-dosing regimens
- Hybrid MIGS combinations (MicroSclerostomy + Canaloplasty or KDB)
- Long-term IOP simulation and monitoring using machine-learning algorithms
These innovations make Minimally Invasive MicroSclerostomy in Korea one of the safest, most effective, and modern MIGS solutions for patients with moderate to advanced glaucoma.
Cost Range (Indicative Estimate)
| Treatment Package | Price (KRW) | Approx. USD | Inclusions |
|---|---|---|---|
| Standard MicroSclerostomy | ₩1,500,000 – ₩2,500,000 | ~$1,100 – $1,900 | Micro-tunnel creation with basic imaging |
| Premium OCT-Guided MicroSclerostomy | ₩3,000,000 – ₩4,500,000 | ~$2,300 – $3,500 | AI planning, OCT targeting, enhanced anti-fibrotic care |
| Hybrid MIGS Micro-Filtration Program | ₩5,000,000 – ₩7,500,000+ | ~$3,800 – $5,600+ | MicroSclerostomy + canal- or trabecular-based MIGS |
Final pricing varies depending on clinic, surgeon expertise, and whether combination MIGS are included.
Popular Clinics in Korea
- B&VIIT Eye Center (Seoul): Leaders in micro-filtration MIGS including MicroSclerostomy.
- Dream Eye Center (Seoul): Known for OCT-guided scleral surgery precision.
- BGN Eye Clinic (Seoul & Busan): Experts in hybrid MIGS combining MicroSclerostomy with canal-based procedures.
- Glory Seoul Eye Clinic: Specialized in controlled filtration MIGS with minimal trauma.
- K-Cure Vision Center (Gangnam): Innovators in AI-guided MicroSclerostomy planning and monitoring.
